AMAALA
24.6.2020 18:13:08 CEST | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coast, has unveiled plans for a new international airport, with a design inspired by the optical illusion of a desert mirage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005664/en/
The terminal and control tower design was conceptualised by UK-based architectural and design firm Foster + Partners, while the airport master plan was designed by Egis, an international consultancy and engineering group. It will incorporate unique design practices, drawing inspiration from its location. The airport is due for completion in 2023 and is estimated to accommodate one million travellers per year once it officially opens.
Commenting on the announcement of the new international airport, the Chief Executive Officer of AMAALA, Nicholas Naples, said: “A gateway to AMAALA, visitors will be greeted by personalised experiences from the moment they step off the plane. From design to personalisation, this will be no ordinary airport. Immersed in the spirit of AMAALA, the airport will create an environment that embodies the philosophy of the destination beyond. This will be a unique space that personifies luxury and marks the start of memorable experiences for the world’s most discerning guests. We are delighted to work with Foster + Partners and Egis on this project.”
On approaching the airport, travellers will see stunning land art from the air. Entering the terminal, visitors will be greeted with a sleek mirrored edifice rising from the desert. The structure takes its inspiration from the surrounding environment, resulting in a mesmerising mirage effect. A spacious courtyard will anchor the terminal and will be complemented by contemporary interiors complete with unique artwork and tailored experiences. The airport will reflect AMAALA’s ultra-luxury hospitality spirit, providing an exclusive private-club experience perfectly encapsulating AMAALA’s pillars of art and culture; wellness and sport; and sea, sun, and lifestyle.
Among the list of amenities provided by the airport are climate-controlled hangars that will be available for private jets as well as a ground transfer service that is accessible from inside the arrival hangar.
Senior Executive Partner of Foster + Partners, Gerard Evenden, said, “Responding to the surrounding landscape, the terminal building will form an exclusive gateway to the AMAALA resort. The passenger experience through the entire building will be akin to a private members club – luxurious and relaxing. Focusing on the themes of art, wellbeing and sport, the design seeks to establish a new model for private terminals that provides a seamless experience from resort to aeroplane.”
Middle East & South Asia Aviation Director of Egis, Jacques Khoriaty , said: “Along with embodying the luxurious spirit of the resort, the AMAALA airport meets the highest environmental design and sustainability standards, is operationally versatile and incorporates the latest airport technology and best practice standards on offer. It has been a privilege to have worked closely with AMAALA to define the requirements of this unique project and we look forward continuing our support all the way through to the opening of the airport in 2023.”
For the airport video rendering, please visit here .
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005664/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom